DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System: Completed Phase I enrollment

Elixir completed enrollment of 15 patients with de novo coronary artery lesions in the open-label, international Phase I DESolve I trial evaluating the DESolve Myolimus Eluting Bioresorbable Coronary ...